Everolimus Teva

/ Abic

Treatment should be initiated and supervised by a physician experienced in the use of anticancer therapies or in the treatment of patients with TSC and therapeutic drug monitoring. Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.
Please refer to the license holder for further details.

Treatment of patients with SEGA associated with tuberous sclerosis Complex (TSC) who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of Everolimus is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.
Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease. The safety and effectiveness of Everolimus in the treatment of patients with carcinoid tumors have not been established.
Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.
Treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of Everolimus in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes.
Treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.
Treatment of unresectable, locally advanced or metastatic, well-differentiated (Grade 1 or Grade 2) nonfunctional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease

Hypersensitivity to the active substance, to other rapamycin derivatives or excipients.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.